Zongertinib CAS No. : 2728667-27-2, BI-1810631, BI1810631 Molecular Weight 535.60 Formula C29H29N9O2 FDA 8/8/2025, Hernexeos, To treat adults with unresectable or metastatic non-squamous non-small cell lung cancer whose tumors have HER2 tyrosine kinase domain activating mutations, as detected by an FDA-approved test, and who have received prior systemic therapy Zongertinib is an orally bioavailable inhibitor of … Continue reading Zongertinib